Bamlanivimab plus etesevimab reduces SARS-CoV-2 viral load
Consenting for treatment in advance to reduce leaving the hospital against medical advice among patients with addiction
22 January 2021How is the pandemic affecting non-covid services?
22 January 2021Bamlanivimab plus etesevimab reduces SARS-CoV-2 viral load
(HealthDay)—Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in patients with mild-to-moderate COVID-19, according to a study published online Jan. 21 in the Journal of the American Medical Association.
